文献速递淋巴瘤

我如何管理复发/难治性弥漫大B细胞淋巴瘤患者

How I manage patients with relapsed/refractory diffuse large B cell lymphoma.
PubMed 文献 · Br J Haematol · 2018-05-29

综述以CORAL研究为框架,讨论复发/难治性弥漫大B细胞淋巴瘤(R/R DLBCL)的管理。 salvage化疗后自体干细胞移植(ASCT)是标准二线治疗,但半数患者因挽救治疗无效无法移植,另半数移植后复发;随机研究中无挽救方案优于其他方案。SCHOLAR-1研究636例难治性DLBCL患者客观缓解率26%(完全缓解7%),中位总生存6.3个月;CAR-T细胞工程结果令人鼓舞,需在明确对照组中进一步研究。

要点

  • 挽救化疗后ASCT是R/R DLBCL的标准二线治疗。
  • 随机研究中无挽救化疗方案优于其他方案。
  • SCHOLAR-1研究难治性DLBCL客观缓解率26%,中位总生存6.3个月。

核心结论

  • 尽管DLBCL一线治疗有进展,患者仍会复发;挽救化疗后ASCT是R/R DLBCL的标准二线治疗。
  • 一半患者因挽救治疗无效无法移植,另一半ASCT后复发;随机研究中无挽救化疗方案优于其他方案。
  • SCHOLAR-1研究636例难治性DLBCL患者客观缓解率26%(完全缓解7%),中位总生存6.3个月。
  • CAR-T细胞工程结果令人鼓舞,需在明确对照组难治患者中进一步研究。

研究设计与样本

  • 综述以协作试验复发侵袭性淋巴瘤(CORAL)为框架构建讨论。
  • 引用多队列回顾性非霍奇金淋巴瘤研究(SCHOLAR-1)纳入636例难治性DLBCL患者。

主要发现

  • 随机研究中无挽救化疗方案优于其他方案。
  • SCHOLAR-1研究中难治性DLBCL患者下一线治疗客观缓解率26%,完全缓解7%,中位总生存6.3个月。
  • 挽救治疗有效后接受移植的DLBCL患者可实现长期生存。
  • CAR-T细胞工程报告了令人鼓舞的结果。

关键数值与推荐

  • 挽救化疗后ASCT是R/R DLBCL的标准二线治疗。
  • SCHOLAR-1研究636例难治性DLBCL患者客观缓解率26%(完全缓解7%),中位总生存6.3个月。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Despite progress in the upfront treatment of diffuse large B cell lymphoma (DLBCL), patients still experience relapses. Salvage chemotherapy followed by autologous stem cell transplantation (ASCT) is the standard second-line treatment for relapsed and refractory (R/R) DLBCL. However, half of the patients will not be eligible for transplantation due to ineffective salvage treatment, and the other half will relapse after ASCT. In randomized studies, no salvage chemotherapy regimen is superior to another. The outcomes are affected by the secondary International Prognostic Index at relapse and various biological factors. The strategy is less clear in patients who require third-line treatment. A multicohort retrospective non-Hodgkin lymphoma research (SCHOLAR-1) study conducted in 636 patients with refractory DLBCL showed an objective response rate of 26% (complete response 7%) to the next line of therapy with a median overall survival of 6·3 months. In the case of a response followed by transplantation, long-term survival can be achieved in DLBCL patients. There is clearly a need for new drugs that improve salvage efficacy. Encouraging results have been reported with chimeric antigen receptor -T cell engineering, warranting further studies in a well-defined control group of refractory patients. The Collaborative Trial in Relapsed Aggressive Lymphoma (CORAL) was used as a handy framework to build the discussion.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Gisselbrecht C, Van Den Neste E. How I manage patients with relapsed/refractory diffuse large B cell lymphoma. Br J Haematol. 2018. PMID: 29808921. doi:10.1111/bjh.15412

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。